PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDimenhydrinate
Dimenhydrinate
Dimenhydrinate (dimenhydrinate) is a small molecule pharmaceutical. Dimenhydrinate was first approved as Dimenhydrinate on 1982-01-01. It is used to treat motion sickness, nausea, vertigo, and vomiting in the USA.
Download report
Favorite
Top OTC Drugs
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
otorhinolaryngologic diseasesD010038
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dimenhydrinate (discontinued: Dimenhydrinate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
airmit aceC2002632023-12-01
dimenhydrinateC2002632026-06-12
dramamineC2002632025-12-23
dramamine - nC2002632024-10-25
dramamine chewable orangeC2002632026-06-23
dramamine dramamine, travel basixC2002632024-11-26
dramamine for kidsC2002632025-09-10
dramamine less drowsyC2002632026-09-04
dramamine less drowsy, lil drug storeC2002632024-11-20
dramamine orangeC2002632026-09-17
Show 7 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
vomiting—D014839R11.1
nausea—D009325R11.0
vertigo—D014717H81.39
motion sickness—D009041T75.3
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AA: Aminoalkyl ethers, systemic antihistamines
— R06AA11: Dimenhydrinate
— R06AA61: Dimenhydrinate, combinations
HCPCS
Code
Description
J1240
Injection, dimenhydrinate, up to 50 mg
Clinical
Clinical Trials
232 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GingivitisD005891—K05.10—234716
Dental plaqueD003773———263213
VomitingD014839—R11.1—1—236
Postoperative nausea and vomitingD020250EFO_0004888——11125
Breast neoplasmsD001943EFO_0003869C501——135
NauseaD009325—R11.0—1—225
Periodontal diseasesD010510—K05.6———145
HypersensitivityD006967EFO_0003785T78.40———235
VertigoD014717—H81.39——13—4
DizzinessD004244—R42———314
Show 31 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PeriodontitisD010518EFO_0000649K05.3——1—45
Kidney diseasesD007674EFO_0003086N08—11—34
Metabolic syndromeD024821EFO_0000195E88.810—11—13
Amyloid plaqueD058225————1—23
Gingival diseasesD005882—K05.1——3——3
BronchiectasisD001987—J47—11——2
MucositisD052016EFO_1001898——11——2
Wounds and injuriesD014947—T14.8—12——2
Skin diseasesD012871—L00-L99—11—12
Avulsion fracturesD000071562———11——1
Show 8 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C80—1——78
Healthy volunteers/patients———21——35
SyndromeD013577———1——23
DermatitisD003872—L30.911——12
ObesityD009765EFO_0001073E66.9—1——12
Multiple myelomaD009101—C90.0—1———1
Drug-related side effects and adverse reactionsD064420—T88.711———1
Drug eruptionsD003875——11———1
StomatitisD013280EFO_1001904K12.1—1———1
PneumothoraxD011030—J93.1111———1
Show 12 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gingival recessionD005889—K06.01———56
CicatrixD002921—L90.51———45
Rheumatoid arthritisD001172EFO_0000685M06.91———12
Triple negative breast neoplasmsD064726——1————1
Atopic dermatitisD003876EFO_0000274L201————1
InflammationD007249MP_0001845—1————1
BlisterD001768——1————1
Tooth extractionD014081——1————1
Bone transplantationD016025——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DehydrationD003681—E86.0————88
Dental implantsD015921——————33
Chronic renal insufficiencyD051436—N18————33
Cognitive dysfunctionD060825—G31.84————33
Fluid therapyD005440——————33
OncogenesD009857——————33
Irritable bowel syndromeD043183EFO_0000555K58————33
Acne vulgarisD000152EFO_0003894L70————22
Positron emission tomography computed tomographyD000072078——————22
XerostomiaD014987—K11.7————22
Show 119 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDimenhydrinate
INNdimenhydrinate
Description
8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine is a diarylmethane.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O
Identifiers
PDB—
CAS-ID523-87-5
RxCUI—
ChEMBL IDCHEMBL1200406
ChEBI ID—
PubChem CID10660
DrugBankDB00985
UNII IDJB937PER5C (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Dimenhydrinate
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,051 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,967 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use